Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Non-Current Assets: 2010-2025

Historic Non-Current Assets for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $19.6 million.

  • Heron Therapeutics' Non-Current Assets fell 23.60% to $19.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.6 million, marking a year-over-year decrease of 23.60%. This contributed to the annual value of $24.1 million for FY2024, which is 28.46% down from last year.
  • According to the latest figures from Q3 2025, Heron Therapeutics' Non-Current Assets is $19.6 million, which was down 7.64% from $21.2 million recorded in Q2 2025.
  • Heron Therapeutics' 5-year Non-Current Assets high stood at $51.3 million for Q4 2021, and its period low was $19.6 million during Q3 2025.
  • Moreover, its 3-year median value for Non-Current Assets was $27.0 million (2024), whereas its average is $29.1 million.
  • In the last 5 years, Heron Therapeutics' Non-Current Assets skyrocketed by 32.95% in 2022 and then declined by 28.46% in 2024.
  • Heron Therapeutics' Non-Current Assets (Quarterly) stood at $51.3 million in 2021, then decreased by 11.25% to $45.5 million in 2022, then declined by 25.89% to $33.7 million in 2023, then dropped by 28.46% to $24.1 million in 2024, then decreased by 23.60% to $19.6 million in 2025.
  • Its last three reported values are $19.6 million in Q3 2025, $21.2 million for Q2 2025, and $22.9 million during Q1 2025.